Book contents
- Neuromuscular Disease: A Case-Based Approach
- Neuromuscular Disease
- Copyright page
- Contents
- Contributors
- Foreword
- Preface to 2nd Edition
- Part I Evaluation and Treatment of Patients with a Neuromuscular Disorder
- Part II Neuromuscular Cases
- Disorders of the Anterior Horn Cell
- Peripheral Neuropathies
- Disorders of the Neuromuscular Junction
- Case 31 Myasthenia Gravis with Acetylcholine Receptor Antibodies (AChR MG)
- Case 32 Myasthenia Gravis with Muscle-Specific Kinase Antibodies (MuSK MG)
- Case 33 Drug-Induced Myasthenia Gravis: Immune Checkpoint Inhibitor (ICI)-Related
- Case 34 Lambert–Eaton Myasthenic Syndrome (LEMS)
- Case 35 Congenital Myasthenic Syndromes (CMS): Dok7
- Myopathies
- Video legends
- Index
- References
Case 32 - Myasthenia Gravis with Muscle-Specific Kinase Antibodies (MuSK MG)
from Disorders of the Neuromuscular Junction
Published online by Cambridge University Press: aN Invalid Date NaN
Book contents
- Neuromuscular Disease: A Case-Based Approach
- Neuromuscular Disease
- Copyright page
- Contents
- Contributors
- Foreword
- Preface to 2nd Edition
- Part I Evaluation and Treatment of Patients with a Neuromuscular Disorder
- Part II Neuromuscular Cases
- Disorders of the Anterior Horn Cell
- Peripheral Neuropathies
- Disorders of the Neuromuscular Junction
- Case 31 Myasthenia Gravis with Acetylcholine Receptor Antibodies (AChR MG)
- Case 32 Myasthenia Gravis with Muscle-Specific Kinase Antibodies (MuSK MG)
- Case 33 Drug-Induced Myasthenia Gravis: Immune Checkpoint Inhibitor (ICI)-Related
- Case 34 Lambert–Eaton Myasthenic Syndrome (LEMS)
- Case 35 Congenital Myasthenic Syndromes (CMS): Dok7
- Myopathies
- Video legends
- Index
- References
Summary
Over a period of months, a 45-year-old woman noticed that she had difficulty raising her arms. She also reported double vision in the evening that, in retrospect, had been present for some years. Three years later, it became difficult to keep her head up without support, to chew, and to swallow, which sometimes worsened over a period of weeks.
Keywords
- Type
- Chapter
- Information
- Neuromuscular DiseaseA Case-Based Approach, pp. 161 - 162Publisher: Cambridge University PressPrint publication year: 2024
References
Suggested Reading
Brauner, S, Eriksson-Dufva, A, Hietala, MA, et al. Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis. JAMA Neurol 2020;77:974–981. doi: 10.1001/jamaneurol.2020.0851.CrossRefGoogle ScholarPubMed
Gilhus, NE. Myasthenia gravis can have consequences for pregnancy and the developing child. Front Neurol 2020 Jun 12;11:554. doi: 10.3389/fneur.2020.00554. PMID: 32595594; PMCID: PMC7304249.CrossRefGoogle ScholarPubMed
Cao, M, Koneczny, I, Vincent, A. Myasthenia gravis with antibodies against muscle specific kinase: an update on clinical features, pathophysiology and treatment. Front Mol Neurosci 2020;13:159. doi: 10.3389/fnmol.2020.00159CrossRefGoogle Scholar
Narayanaswami, P, Sanders, DB, Wolfe, G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 2021;96:114–122. doi:10.1212/WNL.0000000000011124CrossRefGoogle ScholarPubMed
Verschuuren, JJ, Palace, J, Murai, H, et al. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurol 2022;21(2):189–202. doi: 10.1016/S1474-4422(21)00463-4. Erratum in: Lancet Neurol. 2022 Mar;21(3):e3. PMID: 35065041.CrossRefGoogle ScholarPubMed